Quick MRI without dye versus ultrasound for liver cancer checks in cirrhosis
Compares a quick MRI without dye with ultrasound to check for liver cancer in cirrhosis.
Key facts
- Who runs it
- University of Oxford
- Where
- Bournemouth and Oxford, United KingdomSee the 2 sites
- Trial code
- Registry title
- Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 1 May 2025
- Expected to end
- 30 Apr 2039
- Type of study
- Observational
- Treatments tested
- non contrast enhanced MRI
- Record updated
- 22 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis who are at high risk of liver cancer. It compares a quick MRI scan without contrast dye with ultrasound for finding liver cancer early.
- Age
- 18 years or older.
- Sex
- All genders can join.
- Disease stage
- Liver cirrhosis with Child Pugh score A or B, caused by alcohol-related liver disease, MASLD, chronic hepatitis C, chronic hepatitis B or genetic haemochromatosis. Annual risk of liver cancer (HCC) of at least 3% by the aMAP score. People with chronic liver disease who were successfully treated for HCC, have had no recurrence and are back on 6 monthly ultrasound checks can also join.
- Earlier treatment
- People treated for liver cancer (HCC) can join only if there is no recurrence and they are back to 6 monthly ultrasound checks. People with a previous liver transplant cannot join.
- Biomarker or test result
- Annual risk of HCC of at least 3% as measured by the aMAP score.
Main reasons for not taking part
- Cannot have an MRI, or has an allergy to gadolinium contrast
- Pregnant or breast feeding
- Previous liver transplant
- Kidney function (eGFR) below 30 ml/min/1.73m2, or on haemodialysis
- Illness likely to lead to death within 12 months
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- • Participant is willing and able to give informed consent for participation in the study AND; All genders, aged 18 years or above AND; Eligible for HCC US surveillance in the opinion of the local investigators AND; Child Pugh score A or B AND; Diagnosed with liver cirrhosis due to ArLD, MASLD, chronic hepatitis C, chronic hepatitis B, genetic haemochromatosis AND; Have an annual risk of HCC of at least 3% as determined by the aMAP score OR; Participants with chronic liver disease (with or without cirrhosis) who had successful treatment for HCC, have not had a recurrence and have returned to 6 monthly surveillance with USS
Who cannot take part
- • Contraindication to MRI; Known allergy / reaction to intravenous gadolinium contrast; Prisoners; Pregnancy or breast feeding; Previous liver transplant; Participants who are known to have indeterminate liver nodules on prior imaging requiring ongoing follow-up with MRI or CT; Previous HCC treated with curative intent and still being followed up with CT or MRI with contrast for possible recurrence; Estimated glomerular filtration rate of <30 ml/min/1.73m2; Participant is on haemodialysis; Participants who are unlikely to comply with the study procedures in the opinion of the local investigator; In the view of the clinician, if the participant has a co-morbidity likely to lead to death within the following 12 months
Where in United Kingdom
- Bournemouth University HospitalBournemouth, United KingdomContact: Michael Pavlides, DPhilTaking people
- Oxford University Hospitals NHS Foundation TrudtOxford, United KingdomContact: Michael Pavlides, DPhilTaking people
About the trial
What the trial wants to find out
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
Read full original descriptionShow less
Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer.
Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound.
Design and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.
The group in the trial
- non contrast MRI AND standard of care USS
Participants undergo ultrasound every 6 months as per routine clinical care. In addition they undergo research non-contrast enhanced MRI at the same 6 monthly intervals
Treatment: non contrast enhanced MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
- Plain-language title
- Quick MRI without dye versus ultrasound for liver cancer checks in cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 September 2025